Retinoic acid
By selecting your device, the default minimum transfer time will be set.
Add to Complex
Primary Application
Imprint
For what
Blood and Cardiovascular
Immune and Lymphatic
Integumentary
Mitochondrial and Energy Production
Source
Allopathy
For whom
People
All Trans Retinoic Acid (ATRA) is FDA approved in the treatment of promyelocytic leukemia. ATRA is a strong differentiating agent. As such, ATRA has potential as a therapy in a number of cancers, especially in the context of IC medicines. ATRA binds to retinoic acid receptors, and subsequently activates DNA transcription activity to move immature (e.g. malignant) cells toward normal maturation. Consider the use of ATRA in cases of cancer and precancerous lesions, including polyps, actinic keratosis, and others.
Similar ICs
9
603
Imprint
Temozolomide is the most widely used chemotherapeutic agent in the treatment of the most common form of brain cancer, called glioblastoma (GBM). Te...
581
120 k
Imprint
Methylene blue is a dye that was first developed to stain and inactivate certain microbes. It was also one of the first chemotherapeutic medication...
157
50.1 k
Imprint
This compound belongs to the group of benzimidazole carbamates, drugs widely used in human and veterinary medicine against parasitic worms. The mol...
Please select language
Select